Described herein is a novel dosage regimen, and related uses and methods, for a prostaglandin FP receptor agonist (PFPRA) compound topically administered to the skin. The dosage regimen is useful for reduction of subcutaneous fat, for example, in patients who suffer from local excesses of subcutaneo
Described herein is a novel dosage regimen, and related uses and methods, for a prostaglandin FP receptor agonist (PFPRA) compound topically administered to the skin. The dosage regimen is useful for reduction of subcutaneous fat, for example, in patients who suffer from local excesses of subcutaneous fat. A particular advantage of the dosage regimen is the ability to reduce composition exposure and thereby promote convenience and comfort, while maintaining the desired exposure and therapeutic effect in subcutaneous fat. Further provided are kits according to the novel dosage regimen, comprising a PFPRA composition and instructions for use.
대표청구항▼
1. A method for locally reducing body fat in a subject in need thereof, the method comprising the steps of: administering a composition comprising latanoprost to the skin surface; and removing the composition or residue thereof from the skin surface between about 4 hours and about 12 hours, inclusiv
1. A method for locally reducing body fat in a subject in need thereof, the method comprising the steps of: administering a composition comprising latanoprost to the skin surface; and removing the composition or residue thereof from the skin surface between about 4 hours and about 12 hours, inclusive, after said administering; wherein more than about 60 percent of the 24-hour flux of latanoprost or an active metabolite thereof occurs within 4 to 12 hours, inclusive, after the step of administering, and wherein the step of removing is after more than about 60 percent of the 24-hour flux has occurred. 2. The method of claim 1, wherein the removing is between about 4 hours and about 10 hours, inclusive, after said administering. 3. The method of claim 2, wherein the removing is between about 4 hours and about 8 hours, inclusive, after said administering. 4. The method of claim 2, wherein the removing is between about 6 hours and about 10 hours, inclusive, after said administering. 5. A method for locally reducing body fat in a subject in need thereof, the method comprising the steps of: administering a composition comprising latanoprost to the skin surface; and removing the composition or residue thereof from the skin surface between about 4 hours and about 12 hours, inclusive, after said administering; wherein the dermis is fully loaded with latanoprost, an active metabolite thereof, or a combination thereof, within 4 to 12 hours, inclusive, after the administering, and wherein the step of removing is after the dermis is fully loaded. 6. The method of claim 1, wherein the dose frequency is once every 24 hours. 7. The method of claim 1, wherein the body fat is eyelid fat. 8. The method of claim 1, wherein the composition is an ointment. 9. The method of claim 1, wherein the composition comprises petroleum jelly. 10. The method of claim 9, wherein the composition further comprises isopropyl myristate. 11. The method of claim 1, wherein the composition comprises isopropyl myristate. 12. The method of claim 5, wherein the removing is between about 4 hours and about 10 hours, inclusive, after said administering. 13. The method of claim 12, wherein the removing is between about 4 hours and about 8 hours, inclusive, after said administering. 14. The method of claim 12, wherein the removing is between about 6 hours and about 10 hours, inclusive, after said administering. 15. The method of claim 5, wherein the dose frequency is once every 24 hours. 16. The method of claim 5, wherein the body fat is eyelid fat. 17. The method of claim 5, wherein the composition is an ointment. 18. The method of claim 5, wherein the composition comprises petroleum jelly. 19. The method of claim 18, wherein the composition further comprises isopropyl myristate. 20. The method of claim 5, wherein the composition comprises isopropyl myristate.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (71)
Feng Zixia ; Hellberg Mark R., 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension.
Ling, Kah-Hiing John; Yang, Wu; Ni, Jinsong; Yuan, Haiqing; Tang-Liu, Diane D. S., 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Woodward David F. (El Toro CA) Andrews Steven W. (Rancho Santa Marguerita CA) Burk Robert M. (Irvine CA) Garst Michael E. (Newport Beach CA), Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tennenbaum, Tamar; Braiman-Wiksman, Liora; Solominik, Inessa; Meir, Michal, Method and compositions for prevention and treatment of diabetic and aged skin.
Pintor, Jesus J.; Peral, Maria A.; Peterson, Ward M.; Plourde, Jr., Robert; Brown, Edward G.; Yerxa, Benjamin R., Method for reducing intraocular pressure using indole derivatives.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
David F. Woodward ; Steven W. Andrews ; Robert M. Burk ; Michael E. Garst, Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Klimko Peter G. ; Bishop John E. ; Sallee Verney L. ; Zinke Paul W., Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension.
Hellberg, Mark R.; Nixon, Jon C., Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.